These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16400396)

  • 21. Fibrates: where are we now?
    Seth Loomba R; Arora R
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
    Oldemeyer JB; Lund RJ; Koch M; Meares AJ; Dunlay R
    Cardiology; 2000; 94(2):127-8. PubMed ID: 11173785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety considerations with fibrate therapy.
    Davidson MH; Armani A; McKenney JM; Jacobson TA
    Am J Cardiol; 2007 Mar; 99(6A):3C-18C. PubMed ID: 17368275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Jamal SM; Eisenberg MJ; Christopoulos S
    Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report.
    Dalugama C; Pathirage M; Kularatne SAM
    J Med Case Rep; 2018 May; 12(1):143. PubMed ID: 29784023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rhabdomyolysis secondary to simvastatin and phenofibrate].
    Forcadell-Peris MJ; de Diego-Cabanes C
    Semergen; 2014; 40(4):e91-4. PubMed ID: 24768027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.
    Kar S; Chockalingam A
    Am J Ther; 2013 Jan; 20(1):57-60. PubMed ID: 21192242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.
    Wierzbicki AS
    Curr Opin Lipidol; 2010 Aug; 21(4):352-8. PubMed ID: 20625256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myopathy with statin-fibrate combination therapy: clinical considerations.
    Jacobson TA
    Nat Rev Endocrinol; 2009 Sep; 5(9):507-18. PubMed ID: 19636324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
    Catapano AL
    Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE; Sowell MO; Stender M; Qizilbash N
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin safety: a systematic review.
    Law M; Rudnicka AR
    Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rhabdomyolysis and lipid-lowering drugs.
    Tenenbaum A; Fisman EZ; Motro M
    JAMA; 2005 Mar; 293(12):1448; author reply 1448-9. PubMed ID: 15784863
    [No Abstract]   [Full Text] [Related]  

  • 36. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].
    Sirvent AE; Cabezuelo JB; Enríquez R; Amorós F; González C; Reyes A
    Nefrologia; 2001; 21(5):497-500. PubMed ID: 11795020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhabdomyolysis and HMG-CoA reductase inhibitors.
    Omar MA; Wilson JP; Cox TS
    Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for statin-associated rhabdomyolysis.
    Schech S; Graham D; Staffa J; Andrade SE; La Grenade L; Burgess M; Blough D; Stergachis A; Chan KA; Platt R; Shatin D
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):352-8. PubMed ID: 16892458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins and myotoxicity: a therapeutic limitation.
    Tiwari A; Bansal V; Chugh A; Mookhtiar K
    Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
    Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.